Matis, Ilias
Delivoria, Dafni Chrysanthi
Mavroidi, Barbara
Papaevgeniou, Nikoletta
Panoutsou, Stefania
Bellou, Stamatia
Papavasileiou, Konstantinos D.
Linardaki, Zacharoula I.
Stavropoulou, Alexandra V.
Vekrellis, Kostas
Boukos, Nikos
Kolisis, Fragiskos N.
Gonos, Efstathios S.
Margarity, Marigoula
Papadopoulos, Manthos G.
Efthimiopoulos, Spiros
Pelecanou, Maria
Chondrogianni, Niki
Skretas, Georgios
Article History
Received: 6 June 2017
Accepted: 6 September 2017
First Online: 10 October 2017
Change Date: 2 January 2018
Change Type: Correction
Change Details: In the version of this Article originally published, in Fig. 1c–e, on the x axes, the lines labelled ‘Aβ42’ and ‘Aβ42(F19S;L34P)’ grouped the data incorrectly; the line labelled Aβ42 should have grouped the data for Random 1–2 and Clones 1–10, and the line labelled Aβ42(F19S;L34P) should have only grouped the data for Random 1–2 on the right end of the plots and blots. These figures have now been corrected in all versions of the Article.
Competing interests
: G.S. is the inventor on patent applications for AβC5-34, AβC5-116, SOD1C5-4 and other Aβ- and SOD1-targeting peptide macrocyclic sequences described in this article.